G-BA Archives — Page 9 of 10 — German Market Access

What is reference pricing?

If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,

The G-BA, physicians, hospitals, SHI funds or patient organizations can request the assessment of a new method. If the request was accepted,

This new DMP for obesity should consider and combine various therapeutic approaches to offer the best possible care, treat patients with obesity

Early benefit assessments are completed within 12 months, while method assessments used to take around 3 years. In 2020, the G-BA introduced

Since 2011, 7 new laws were added to AMNOG to dictate the early benefit assessment of drugs. Therefore, it is often called

The G-BA has now completed its benefit assessment of the CAR-T therapy, Tecartus, which is indicated for the treatment of mantle cell

The AMNOG law dictates that every pharmaceutical product with a new chemical entity which received its marketing authorization on or after 1

The G-BA has recently published its annual report from last year, 2020. Key statistics on the early benefit assessments The number of

Hospitals can treat patients with novel methods as soon as they become available. The treatment is reimbursed by SHI funds within the

It’s been a long time in the making, but now the G-BA finally accepted a compromise on joint HTAs conducted at the